<DOC>
	<DOCNO>NCT00044447</DOCNO>
	<brief_summary>The purpose study assess efficacy safety Amaryl add Metformin Thiazolidinedione ( TZD ) non-insulin dependent diabetes mellitus ( NIDDM ) patient .</brief_summary>
	<brief_title>Evaluate Role Adding Amaryl Non-Insulin Dependent Diabetes Mellitus Patients Unresponsive Maximum Dose Metformin &amp; Thiazolidinedione</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>2,4-thiazolidinedione</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Patients must give sign informed consent . Males females 18 80 year old . Female patient must surgically sterile , postmenopausal , use accept method birth control ( i.e. , oral contraceptive , intrauterine device , Norplant® system , Depo Provera® , spermicide condom ) . Female patient childbearing potential must negative serum pregnancy test advise become pregnant study . At least 1 year history NIDDM performing home blood glucose monitoring . Patients must BMI &gt; 26 &lt; 42 kg/m2 baseline ( week 0 ) . Patients must HbA1C &gt; 7.5 % &lt; 9.5 % screen ( week 4 ) . Patients must evidence insulin secretory capacity ( fast Cpeptide concentration &gt; equal 0.27 nmol/l stabilization period ) . Patients must FPG &gt; 130 mg/dl &lt; 235 mg/dl prior ( within 4872 hour ) randomization Visit 1 Week 0 . Patients must receive current diabetic therapy stable dos metformin ( dose 1.02.5gm/day ) , metformin extend release maximum dose 2 gm/day half maximum maximum dose thiazolidinedione least 3 month . Patients must able understand willing adhere compliant study protocol . Patients require insulin therapy currently sulfonylurea . Patients history hypersensitivity sulfonylurea . Patients past history severe hypoglycemia reaction current antidiabetic therapy require medical attention . Patients history acute metabolic complication hyperosmolar coma ketonuria . Patients clinically significant abnormal baseline laboratory value ( hematology , blood chemistry urinalysis ) define disease condition , opinion investigator may either put patient risk participation study , may influence result study , patient 's ability participate complete study . Should laboratory value , upon initial screening , substantially outside normal range , test repeat . Patients increase thiazolidinedione medication within 2 month enter study ( Visit 0 ) . Patients increase metformin medication within 1 month enter study ( Visit 0 ) . Patients whose body weight change 2 % patient &lt; 250 pound 3 % patient &gt; = 250 pound , 4 week stabilization period compare weight screen visit 0 ( week 4 ) . Patients acute infection . Patients receive drug ( i.e . chemotherapy agent ) welldefined potential toxicity major organ system three month prior study . Patients clinically significant renal hepatic disease ( i.e . ALT &gt; 2.5 x upper limit normal ) gastrointestinal disorder may interfere absorption study drug . Patients allergic sulfonamides excipients . Patients history alcohol drug abuse . Pregnant lactating female exclude . Patients history psychosis , emotional intellectual problem could impair ability patient participate study complete study . Patients participate investigational study within 30 day prior Visit 0 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2008</verification_date>
</DOC>